^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA mutation

    i
    Other names: BRCA, Breast cancer, early onset
    Related biomarkers:
    Expression
    CNA
    Others
    1d
    PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=126, Completed, PharmaMar | Recruiting --> Completed
    Trial completion • First-in-human
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    ecubectedin (PM14)
    2d
    Metastatic Meningioma with Systemic Involvement: Discussion of Molecular, Genomic, and Radiological Features. (PubMed, World Neurosurg)
    Extra-CNS metastatic meningiomas pose significant diagnostic and therapeutic challenges. High-grade meningiomas are more likely to metastasize; early detection of metastatic spread is challenging. Our findings highlight the need for a multidisciplinary approach with close follow-up, especially in recurrent or high-grade meningiomas with distinct mutations.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • BAP1 (BRCA1 Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BRCA (Breast cancer early onset)
    |
    BRCA1 mutation • BRCA mutation
    |
    everolimus • Ninlaro (ixazomib) • Tazverik (tazemetostat)
    3d
    From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. (PubMed, Drugs Real World Outcomes)
    Genomic testing application remained limited and uneven across centers. Most eligible patients received olaparib; TN patients seemed to benefit most.
    Clinical • Journal • Real-world evidence • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib)
    5d
    LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling. (PubMed, Genome Biol)
    Our findings unveil a novel regulatory mechanism of L1 m6A that governs the DNA damage repair response, providing a potential strategy of targeting METTL3 in combination with PARPi for cancer therapy.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • METTL3 (Methyltransferase Like 3)
    |
    BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib)
    5d
    Cervical cancer with BRCA1 gene mutations: case reports and literature review. (PubMed, Front Oncol)
    In patients with cervical cancer, BRCA testing holds important clinical value, particularly for the management of those with a significant family history of malignancy or confirmed hereditary predisposition. Appropriate genetic counseling plays an essential role in guiding preventive strategies, facilitating early diagnosis, and supporting informed decision-making regarding potential prophylactic interventions.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA1 mutation • BRCA mutation
    5d
    Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers. (PubMed, Oncol Rev)
    Future directions emphasize next-generation ICIs, optimized combination regimens, and AI-driven biomarker integration to achieve durable, personalized treatments. This review underscores the potential of immunotherapy to redefine TNBC management while highlighting the imperative for continued innovation to address unmet clinical needs.
    Review • Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
    6d
    JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models. (PubMed, Br J Cancer)
    These results suggest the scientific rationale for further clinical development of JPI-547 for treating both PARP inhibitor-sensitive patients and those resistant to first-generation PARP inhibitors in BRCA-mutated cancers.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • nesuparib (JPI-547)
    6d
    Two decades of PARP inhibitor synthetic lethality in cancer. (PubMed, Nature)
    The significance of these discoveries spread beyond BRCA1-mutant and BRCA2-mutant cancers: the synthetic lethal concept of the BRCA-PARP inhibitor effect highlighted the myriad levels of functional redundancy that exist in tumour cells and stimulated the search for other tumour-specific synthetic lethal effects that could be exploited therapeutically. Here we distill the learnings from the past two decades in this field.
    Review • Journal • BRCA Biomarker • PARP Biomarker • BRCA Companion diagnostic • PARP Companion diagnostic
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    6d
    Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial. (PubMed, Int J Gynecol Cancer)
    These data confirm that the use of olaparib as long-term maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer is tolerable. Adverse events occurred early, were manageable, and few occurred with late onset.
    Clinical • P3 data • Journal • Adverse events • BRCA Biomarker • PARP Biomarker • Platinum sensitive
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    7d
    Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial (clinicaltrials.gov)
    P2, N=30, Recruiting, Massachusetts General Hospital | Trial completion date: Mar 2027 --> Apr 2028 | Trial primary completion date: Aug 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA1 mutation • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation
    |
    Guardant360® CDx
    |
    Talzenna (talazoparib)
    7d
    FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=85, Active, not recruiting, Fusion Pharmaceuticals Inc. | Trial completion date: Aug 2030 --> May 2027 | Trial primary completion date: Jan 2030 --> May 2027
    Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation • FOLH1 positive
    |
    Lynparza (olaparib) • FPI-2265
    9d
    RAINFOL™-07: Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer (clinicaltrials.gov)
    P3, N=688, Not yet recruiting, Genmab
    New P3 trial • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • HRD • BRCA mutation
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • paclitaxel • Rina-S (rinatabart sesutecan)